Genome-wide analysis of 102,084 migraine cases identifies 123 risk loci and subtype-specific risk alleles - Hautakangas, Heidi; Winsvold, Bendik S.; Ruotsalainen, Sanni E.; Bjornsdottir, Gyda; Harder, Aster V. E.; Kogelman, Lisette J. A.; Thomas, Laurent F.; Noordam, Raymond; Benner, Christian; Gormley, Padhraig; Artto, Ville; Banasik, Karina; et al. (medRxiv, 2021)
Migraine affects over a billion individuals worldwide but its genetic underpinning remains largely unknown. This genome-wide association study (GWAS) of 102,084 migraine cases and 771,257 controls identified 123 loci of which 86 are novel. The loci provide an opportunity to evaluate shared and distinct genetic components in the two main migraine subtypes: migraine with aura and migraine without aura. A stratification of the risk loci using 29,679 cases with subtype information, of which approximately half have never been used in a GWAS before, indicated three risk variants that appear specific for migraine with aura (in HMOX2, CACNA1A and MPPED2), two that appear specific for migraine without aura (near SPINK2 and near FECH), and nine that increase susceptibility for migraine regardless of subtype. The new risk loci include genes encoding recent migraine-specific drug targets, namely calcitonin gene-related peptide (CALCA/CALCB) and serotonin 1F receptor (HTR1F). Overall, genomic annotations among migraine-associated variants were enriched in both vascular and central nervous system tissue/cell types supporting unequivocally that neurovascular mechanisms underlie migraine pathophysiology.Competing Interest StatementGB, TET, SHM, HS and KS are employees of deCODE genetics/Amgen. PG was an employee of Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., Kenilworth, NJ, USA. TF reports possible competing interest for Electrocore (participation in clinical studies), Novartis (speakers’ honoraria, participation in advisory boards, participation in clinical studies), Teva (speakers’ honoraria, participation in advisory boards), Lilly (speakers’ honoraria, participation in clinical studies), Bayer (speakers’ honoraria). MK has served on Advisory Boards for MSD and Allergan; has received funding for travel and/or speaker honoraria from MSD, Allergan, TEVA, Novartis, and Genzyme; has received compensation for producing educational material from TEVA and Allergan; has received research support from Helsinki University Central Hospital; and holds stock/stock options and/or has received Board of Directors compensation from Helsinki Headache Center. TK reports having received honoraria from Eli Lilly, Newsenselab, and Total for providing methodological advice and from the BMJ for editorial services. AP is the Scientific Director of the public-private partnership project FinnGen that has 12 industry partners that provide funding for the FinnGen project. VA has served on advisory board for Allergan and Lilly. Other authors report no conflicts of interests.Funding StatementdeCODE received financial support from the European Commission to the NeuroPain project (FP7#HEALTH-2013-602891-2) and painFACT project (H2020-2020-848099) and the National Institutes of Health (R01DE022905). The GeneRISK study was funded by Business Finland through the Personalized Diagnostics and Care program coordinated by SalWe Ltd (Grant No 3986/31/2013). The Trøndelag Health Study (HUNT) is a collaboration between the HUNT Research Centre (Faculty of Medicine and Health Sciences, NTNU, Norwegian University of Science and Technology), Trøndelag County Council, Central Norway Regional Health Authority, and the Norwegian Institute of Public Health. The genotyping was financed by the National Institute of health (NIH), University of Michigan, The Norwegian Research council, and Central Norway Regional Health Authority and the Faculty of Medicine and Health Sciences, Norwegian University of Science and Technology (NTNU). The NEO study is supported by the participating Departments, the Division and the Board of Directors of the Leiden University Medical Centre, and by the Leiden University, Research Profile Area ’Vascular and Regenerative Medicine’. DIC is supported in part by the US National Institute of Neurological Disorders and Stroke (NINDS) of the US National Institutes of Health (NIH) (grant numbers R21NS09296 and R21NS104398). EW was supported by the Finnish innovation fund Sitra and Finska Läkaresällskapet. MP was supported by the Academy of Finland (Grant Nos 288509, 312076, 336825) and the Sigrid Juselius Foundation. SR was supported by the Academy of Finland Center of Excellence in Complex Disease Genetics (Grant No 312062), the Finnish Foundation for Cardiovascular Research, the Sigrid Juselius Foundation and University of Helsinki HiLIFE Fellow and Grand Challenge grants. TFH and KB are supported by The Novo Nordisk Foundation (NNF14CC0001 and NNF17OC0027594). TFH is supported by CANDY foundation (CEHEAD).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:All participating studies were approved by local research ethics committees and written informed consent was obtained from all study participants. 23andMe: All participants have provided informed consent and filled an online survey according to 23andMe’s human subjects protocol, which was reviewed and approved by Ethical & Independent Review Services, a private institutional review board. GeneRISK: All study participants have given their informed consent, and the study protocol has been approved by the Ethical Committee of the Helsinki and Uusimaa Hospital district. HUNT All-in Headache: Written informed consent was obtained from all participants, and The Regional Committee for Medical and Health Research Ethics approved the study (ref. 2015/576). UKBB: UK Biobank received ethical approval from the North West Multi-centre Research Ethics Committee (MREC) and informed consent has been obtained from participants. This research has been conducted using the UK Biobank Resource under Application Number 22627. DBDS: Written informed consent was obtained from all participants in DBDS. DBDS has secured necessary permissions and approval from the Danish Data Protection Agency (2007-58-0015) and the Scientific Ethical Committee system (M-20090237). deCODE: Approval for these studies was provided by the National Bioethics Committee (approval no. VSN 19-158). All participants who donated blood signed informed consent. The personal identities of participants were encrypted using a third-party system approved and monitored by the Icelandic Data Protection Authority. LUMINA: The LUMINA project was approved by the medical ethics committee of the Leiden University Medical Center. All respondents provided written informed consent. NEO: Written informed consent was obtained from all participants, and the local ethics committee approved the study. For all the participating studies, an approval was received to use the data in the present work.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesResults for 8,117 genome-wide significant SNP associations (P < 5x10-8) from the meta-analysis including 23andMe data will be available on the International Headache Genetics Consortium (IHGC) website (http://www.headachegenetics.org/). Genome-wide summary statistics for the four other study collections except 23andMe will be available as described on the IHGC website. The full GWAS summary statistics for the 23andMe discovery data set will be made available through 23andMe to qualified researchers under an agreement with 23andMe that protects the privacy of the 23andMe participants. Please visit research.23andme.com/collaborate/#publication for more information and to apply to access the data. http://www.headachegenetics.org/ https://research.23andme.com/collaborate/#publication